8-K: Kezar Reports Q2 Results, Advances Autoimmune Hepatitis Drug

Kezar Life Sciences announced second quarter 2025 financial results, highlighted by the FDA's removal of a partial clinical hold on its PORTOLA trial for autoimmune hepatitis and plans for a registration-enabling study.

Summary

• Kezar Life Sciences reported financial results for the second quarter ended June 30, 2025, alongside a significant business update regarding its lead drug candidate, zetomipzomib.
• The U.S. Food and Drug Administration (FDA) removed the partial clinical hold on the completed PORTOLA Phase 2a clinical trial evaluating zetomipzomib for autoimmune hepatitis (AIH).
• A Type C meeting request has been submitted to the FDA to discuss the AIH development plan for zetomipzomib, with a proposed registration-enabling study, scheduled for the fourth quarter of 2025.
• Topline results from the PORTOLA Phase 2a trial showed that 36% (5 of 14) of zetomipzomib-treated relapsed or refractory AIH patients achieved a complete biochemical response and clinically significant steroid taper to 5 mg/day or less by 6 months, compared to 0 of 7 placebo patients.
• The median duration of response in zetomipzomib patients achieving a complete response was 27.6 weeks, with no disease flares reported in these patients during the study.
• Cash, cash equivalents, and marketable securities totaled $100.8 million as of June 30, 2025, a decrease from $132.2 million as of December 31, 2024, primarily due to cash used in operations.
• Research and development (R&D) expenses decreased by $6.7 million to $9.6 million in Q2 2025, down from $16.3 million in Q2 2024, due to decreased clinical activities and personnel costs.
• General and administrative (G&A) expenses decreased by $0.6 million to $5.0 million in Q2 2025, down from $5.6 million in Q2 2024.
• Net loss for Q2 2025 improved to $13.7 million, or $1.87 per basic and diluted common share, compared to a net loss of $21.5 million, or $2.96 per basic and diluted common share, for Q2 2024.

Sentiment

Score: 8

Explanation: The sentiment is highly positive due to the significant clinical progress, particularly the FDA's removal of the clinical hold and the strong Phase 2a efficacy data for zetomipzomib in autoimmune hepatitis. This de-risks the program considerably and sets the stage for pivotal trials. Financial results also showed improved net loss and reduced expenses, contributing to the positive outlook, despite ongoing cash burn typical for a clinical-stage biotech.

Positives

• FDA removed the partial clinical hold on the PORTOLA Phase 2a trial for zetomipzomib in autoimmune hepatitis, clearing a significant regulatory hurdle.
• Positive topline results from the PORTOLA Phase 2a trial demonstrated a 36% complete biochemical response rate with steroid taper in relapsed or refractory AIH patients, significantly outperforming placebo (0%).
• Zetomipzomib showed a favorable safety profile during the 6-month blinded treatment period.
• The company submitted a Type C meeting request to the FDA for Q4 2025 to discuss a proposed registration-enabling study for zetomipzomib in AIH, indicating clear progress towards pivotal trials.
• PORTOLA Phase 2a data and biomarker data were selected for oral and poster presentations, respectively, at The Liver Meeting 2025, enhancing visibility and scientific validation.
• Net loss significantly improved to $13.7 million in Q2 2025 from $21.5 million in Q2 2024.
• Research and development expenses decreased by $6.7 million, reflecting efficient management of clinical trial closeouts and reduced operational costs.
• General and administrative expenses also decreased by $0.6 million, contributing to overall cost reduction.

Negatives

• Cash, cash equivalents, and marketable securities decreased to $100.8 million as of June 30, 2025, from $132.2 million as of December 31, 2024, indicating continued cash burn from operations.
• The company continues to report a net loss, albeit reduced, of $13.7 million for the second quarter of 2025.

Risks

• Unexpected safety or efficacy data could be observed during future clinical studies, potentially impacting development or regulatory approval.
• Difficulties may arise in enrolling and conducting future clinical trials, which could delay timelines.
• Changes in expected or existing competition could affect market potential for zetomipzomib.
• The regulatory environment may change, or the uncertainties and timing of the regulatory approval process could lead to delays or failure to obtain approval.
• Unexpected litigation or other disputes could arise, impacting financial resources and operational focus.

Future Outlook

Kezar Life Sciences is on track with its clinical development and regulatory submission plan for zetomipzomib in autoimmune hepatitis. The company has proposed a registration-enabling study and anticipates a Type C meeting with the FDA in the fourth quarter of 2025 to align on the next trial design. Management believes zetomipzomib has the potential to positively transform the lives of patients with autoimmune hepatitis and is committed to working closely with the FDA.

Management Comments

• "We are on track with our clinical development and regulatory submission plan for zetomipzomib in autoimmune hepatitis."
• "We are committed to working closely with the FDA to align on our next trial design, which we have proposed as a registration-enabling study."
• "The Type C meeting will be an important milestone as we continue to believe that zetomipzomib has the potential to positively transform the lives of patients living with autoimmune hepatitis."

Industry Context

This announcement positions Kezar Life Sciences as a key player in the development of novel small molecule therapeutics for immune-mediated diseases, specifically autoimmune hepatitis. The progress with zetomipzomib, a first-in-class selective immunoproteasome inhibitor, highlights the ongoing innovation in the biotech sector to address unmet medical needs. The FDA's removal of a clinical hold is a significant de-risking event in drug development, potentially accelerating the path to market for a new treatment in a challenging disease area. The focus on a registration-enabling study indicates a mature stage of clinical development, moving beyond early-phase exploration.

Comparison to Industry Standards

• The filing does not provide specific comparable companies, projects, or results for direct assessment against industry standards. However, the 36% complete biochemical response rate with steroid taper in relapsed/refractory AIH patients for zetomipzomib in a Phase 2a trial is a strong signal, especially compared to the 0% in the placebo group, suggesting a potentially competitive efficacy profile for a first-in-class mechanism in this indication.

Management Changes

Stakeholder Impact

• **Shareholders:** Positive clinical and regulatory news (FDA hold removal, strong Phase 2a data) could lead to increased investor confidence and potential share price appreciation. However, continued cash burn remains a factor.
• **Patients (Autoimmune Hepatitis):** The progress of zetomipzomib offers hope for a new, potentially transformative treatment option for a disease with unmet needs.
• **Employees:** The promotion of Zung To to Chief Development Officer indicates internal growth opportunities and stable leadership in key development areas.
• **Regulatory Authorities (FDA):** Ongoing collaboration through Type C meetings and responses to clinical holds demonstrates the company's commitment to regulatory compliance and partnership.

Next Steps

• Hold a Type C meeting with the FDA during the fourth quarter of 2025 to discuss the development plan for zetomipzomib in autoimmune hepatitis, including a proposed registration-enabling study.
• Present PORTOLA Phase 2a data in an oral presentation at The Liver Meeting 2025, taking place November 7-11, in Washington, DC.
• Present PORTOLA biomarker data in a poster presentation at The Liver Meeting 2025.
• Continue efforts to remove the clinical hold on zetomipzomib in lupus nephritis by engaging with the FDA Division of Rheumatology and Transplant Medicine.

Key Dates

Recommendation

The FDA's removal of the partial clinical hold on zetomipzomib for autoimmune hepatitis, coupled with compelling Phase 2a efficacy data (36% CR vs. 0% placebo) and a favorable safety profile, significantly de-risks the program and positions it for a potential registration-enabling study. While the company continues to operate at a net loss and burn cash, these are typical for a clinical-stage biotech. The clear path forward with the FDA and the strong clinical signal make Kezar Life Sciences an attractive 'buy' for investors seeking exposure to a promising, first-in-class therapeutic in a high-need indication.

Keywords

Biotechnology, Autoimmune Hepatitis, Zetomipzomib, Clinical Trial, FDA, Immunoproteasome Inhibitor, Kezar Life Sciences, KZR, Drug Development, Phase 2a